Europe's AgTech Race: Why the Netherlands Is Losing Its Edge

Jan de Vries · 2026-10-30

The Netherlands has built a reputation as Europe's agricultural powerhouse. Think cutting-edge greenhouses, world-class seed breeders, and a food production ecosystem that punches way above its weight. But a new report suggests that crown might be slipping. Invest-NL, the Dutch national investment institution, just published a deep dive into the country's agrifood biotech sector. Their conclusion? The Netherlands is great at starting things but struggles to finish them. And that gap could cost the economy billions. ### The Innovation Paradox Here's the weird part. The Netherlands accounts for 3.3% of BioTech startups worldwide. That's impressive for a country of 17 million people. But when you look at scale-ups—companies that have grown past the startup phase—that share drops to just 1.3%. So what's happening? The report, based on interviews with over 150 entrepreneurs, investors, and policymakers, points to three recurring bottlenecks: - Too few promising technologies become scalable ventures - Regulatory and validation processes delay market entry - Insufficient financing prevents companies from reaching industrial production In other words, the science is there. The business machinery isn't. ### The Cost of Waiting Invest-NL estimates that fixing these barriers could unlock an extra €17 billion (about $18.5 billion) in annual revenue by 2040. That's not pocket change. In a best-case scenario, Dutch agrifood biotech revenues could hit €25 billion ($27 billion) annually. Under current conditions, they'd stall at around €8–9 billion ($8.7–9.8 billion). > "The Netherlands doesn't need to manufacture everything domestically. It needs to retain the knowledge, IP, and specialised capabilities that matter." — Invest-NL report That's a key insight. The goal isn't isolationism. It's about keeping the high-value parts of the value chain—the research, the patents, the company headquarters—while tapping into European production networks where it makes sense. ### Eight to Ten Years for a Yes One of the most frustrating hurdles involves biological crop protection. These are alternatives to chemical pesticides, and Dutch companies are developing some promising ones. But getting European regulatory approval can take eight to ten years. Why? Because the existing frameworks were designed for chemicals, not biologicals. So some companies just launch in Brazil or the United States first, where the process moves faster. Invest-NL warns that Europe could lose ground in a market that might grow seven- to tenfold by 2040. Food biotech faces similar delays. Novel ingredients take one to three years longer to approve in Europe than in the US. And building a first commercial production facility? That can cost tens or even hundreds of millions of euros. ### A Call for Smarter Regulation The report isn't asking for a race to the bottom on safety. Far from it. Instead, it suggests regulators offer earlier guidance, more predictable assessments, and opportunities for real-world validation. That seems reasonable. After all, innovation isn't the issue—the Netherlands has plenty of that. The challenge is turning brilliant science into scalable businesses before other countries beat them to it. For now, the ball is in the policymakers' court. And the clock is ticking.